Biolinerx Ltd., of Tel Aviv, Israel, said it started a phase I/II trial for BL-8040 in combination with standard-of-care immunosuppressive therapy as a treatment for two bone marrow failure conditions: hypoplastic myelodysplastic syndrome (hMDS) and aplastic anemia (AA).